UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000016165
Receipt number R000018763
Scientific Title An exploratory study to evaluate molecular predictive and/or prognostic factors of benefit from a randomized, phase III trial of sequential capecitabine/5FU plus bevacizumab (Cape/5FU-Bmab) to capecitabine/5FU plus oxaliplatin plus bevacizumab (CapeOX/mFOLOFX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer.
Date of disclosure of the study information 2015/01/09
Last modified on 2021/04/09 09:28:36

No. Disposal Last modified on Item of update
1 Insert 2015/01/09 00:22:18
2 Update 2018/06/25 14:52:12 Recruitment status
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
3 Update 2018/06/29 13:10:03 Recruitment status
4 Update 2019/04/13 16:25:58 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Middle name of lead principal investigator
Last name of lead principal investigator
Organization
Organization
Division name
Division name
Zip code
Address
Address
TEL
Email

Last name of contact person

Last name of contact person
Organization
Organization
Division name
Zip code
Address
Address
TEL
Email
Organization
Organization
Division name
Division name
Address
TEL
Email
Name of primary person or sponsor
Institute
Institute
Department
Organization
Organization
Organization
Division
Organization1
Address1
Tel1
Organization
Organization
Address
Address
Tel
Email
5 Update 2019/04/13 16:34:47 Number of participants that the trial has enrolled
6 Update 2019/04/13 16:35:45 Date of IRB
7 Update 2021/03/16 11:42:36 Results Delayed
Results Delay Reason
Results Delay Reason
8 Update 2021/04/09 09:28:36 Recruitment status